Mary Flack

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 627 citations

Autoimmune Disease, Medicine, Clinical Trials +6

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 504 citations · Full text

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

Kristian Reich, Melinda Gooderham, Diamant Thaçi et al. · The Lancet · 2019 · 286 citations

Rheumatology, Autoimmune Disease, Active-comparator-controlled Phase 3 +8

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

Andrew Blauvelt, Craig L. Leonardi, Melinda Gooderham et al. · JAMA Dermatology · 2020 · 201 citations · Full text

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta<scp>IMM</scp> phase 2/3 trial

Mamitaro Ohtsuki, Hideki Fujita, Keiko Suzaki et al. · The Journal of Dermatology · 2019 · 92 citations · Full text